GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk Health 5 hours 2 min read
Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.
Open original source